B7-H3, also known as CD276, is an immunoregulatory protein that is overexpressed in tumour tissue, notably in lung, breast, ovarian, gastric, and brain cancer, as well as squamous cell carcinoma ...

Concept: B7-H3 is an immunoregulatory protein expressed on the surface of DIPG tumor cells. Impact: These results from the BrainChild-03 trial warrant further investigation of B7-H3 CAR T-cell therapy ...

We used a unique 3D microfluidic model of tumors to investigate the mechanisms of treatment resistance to CAR-T cells that were designed to target B7-H3, a common antigen in solid tumor cancers.

The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma, a rare form of bone cancer with no FDA-approved treatments. The coveted ...

CAR-T Cell Therapies: Preclinical studies suggest B7-H3 Inhibitors as a viable target for chimeric antigen receptor (CAR)-T cells, offering potential for solid tumor immunotherapy. 3. Addressing Unmet ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen ... B7-H3 for diffuse intrinsic pontine glioma, or DIPG, a rare incurable pediatric brain tumor.